ABRAZO SCOTTSDALE CAMPUS — History
CCN 030083 | 3-year financial timeline | COVID resilience: 60/100
🛡️ Public data only — no PHI permitted on this instance.
$117M
Latest Revenue (FY2022)
+4.8%
Revenue CAGR (3yr)
2.4%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $107M | $122M | $117M | -3.9% | +4.8% |
| Operating Expenses | $104M | $112M | $115M | +2.6% | +5.0% |
| Operating Margin | 2.8% | 8.6% | 2.4% | -72.0% | -7.6% |
| Net Income | $3M | $11M | $3M | -73.1% | -3.1% |
| Licensed Beds | 120 | 128 | 128 | +0.0% | +3.3% |
| Total Patient Days | 18,021 | 20,912 | 18,415 | -11.9% | +1.1% |
| Medicare Day % | 24% | 20% | 20% | +3.1% | -7.7% |
| Medicaid Day % | 6% | 5% | 6% | +31.2% | +4.6% |
COVID Impact & Recovery
Resilience Score: 60/100 — Moderate — some COVID impact but recovering
Revenue recovery from FY2020 to FY2022: +9.9% ($107M → $117M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▼ Declining
Beds▲ Growing
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+4.8%
This Hospital
+7.6%
State Avg
Latest Margin
2.4%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $123M | 2.2% |
| FY2024 (proj) | $128M | 2.0% |
| FY2025 (proj) | $133M | 1.8% |